Foghorn Therapeutics (FHTX) Competitors $7.86 +0.06 (+0.77%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends FHTX vs. CCCC, ZIOP, XNCR, IMCR, NRIX, KNSA, ARVN, NTLA, OCUL, and SYREShould you be buying Foghorn Therapeutics stock or one of its competitors? The main competitors of Foghorn Therapeutics include C4 Therapeutics (CCCC), ZIOPHARM Oncology (ZIOP), Xencor (XNCR), Immunocore (IMCR), Nurix Therapeutics (NRIX), Kiniksa Pharmaceuticals (KNSA), Arvinas (ARVN), Intellia Therapeutics (NTLA), Ocular Therapeutix (OCUL), and Spyre Therapeutics (SYRE). These companies are all part of the "medical" sector. Foghorn Therapeutics vs. C4 Therapeutics ZIOPHARM Oncology Xencor Immunocore Nurix Therapeutics Kiniksa Pharmaceuticals Arvinas Intellia Therapeutics Ocular Therapeutix Spyre Therapeutics C4 Therapeutics (NASDAQ:CCCC) and Foghorn Therapeutics (NASDAQ:FHTX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, community ranking, risk, analyst recommendations, institutional ownership, valuation and earnings. Do analysts rate CCCC or FHTX? C4 Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 146.91%. Foghorn Therapeutics has a consensus target price of $16.00, indicating a potential upside of 103.56%. Given C4 Therapeutics' higher probable upside, equities research analysts clearly believe C4 Therapeutics is more favorable than Foghorn Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score C4 Therapeutics 0 Sell rating(s) 4 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Foghorn Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media refer more to CCCC or FHTX? In the previous week, C4 Therapeutics had 7 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 7 mentions for C4 Therapeutics and 0 mentions for Foghorn Therapeutics. C4 Therapeutics' average media sentiment score of 0.57 beat Foghorn Therapeutics' score of 0.00 indicating that C4 Therapeutics is being referred to more favorably in the media. Company Overall Sentiment C4 Therapeutics Positive Foghorn Therapeutics Neutral Which has preferable earnings & valuation, CCCC or FHTX? Foghorn Therapeutics has higher revenue and earnings than C4 Therapeutics. Foghorn Therapeutics is trading at a lower price-to-earnings ratio than C4 Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioC4 Therapeutics$20.76M13.77-$132.49M-$1.70-2.38Foghorn Therapeutics$34.15M12.79-$98.43M-$1.92-4.09 Is CCCC or FHTX more profitable? C4 Therapeutics has a net margin of -313.35% compared to Foghorn Therapeutics' net margin of -357.53%. Foghorn Therapeutics' return on equity of 0.00% beat C4 Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets C4 Therapeutics-313.35% -42.45% -27.55% Foghorn Therapeutics -357.53%N/A -30.98% Which has more risk & volatility, CCCC or FHTX? C4 Therapeutics has a beta of 3.04, indicating that its share price is 204% more volatile than the S&P 500. Comparatively, Foghorn Therapeutics has a beta of 3.14, indicating that its share price is 214% more volatile than the S&P 500. Do institutionals and insiders believe in CCCC or FHTX? 78.8% of C4 Therapeutics shares are held by institutional investors. Comparatively, 61.6% of Foghorn Therapeutics shares are held by institutional investors. 8.6% of C4 Therapeutics shares are held by insiders. Comparatively, 9.1% of Foghorn Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor CCCC or FHTX? Foghorn Therapeutics received 10 more outperform votes than C4 Therapeutics when rated by MarketBeat users. Likewise, 61.02% of users gave Foghorn Therapeutics an outperform vote while only 38.24% of users gave C4 Therapeutics an outperform vote. CompanyUnderperformOutperformC4 TherapeuticsOutperform Votes2638.24% Underperform Votes4261.76% Foghorn TherapeuticsOutperform Votes3661.02% Underperform Votes2338.98% SummaryC4 Therapeutics and Foghorn Therapeutics tied by winning 9 of the 18 factors compared between the two stocks. Ad Wyatt Investment ResearchMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Get Foghorn Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FHTX vs. The Competition Export to ExcelMetricFoghorn TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$433.63M$6.49B$5.07B$8.90BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-4.094.8587.8613.46Price / Sales12.79374.821,228.8287.66Price / CashN/A52.5939.5136.27Price / Book-15.4110.216.946.30Net Income-$98.43M$153.61M$119.12M$225.93M7 Day Performance-10.68%-2.00%-1.84%-1.32%1 Month Performance8.71%-7.47%-3.65%0.60%1 Year Performance91.24%31.80%31.64%26.23% Foghorn Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FHTXFoghorn Therapeutics2.6424 of 5 stars$7.86+0.8%$16.00+103.6%+91.2%$433.63M$34.15M-4.09120CCCCC4 Therapeutics2.652 of 5 stars$4.05-2.4%$10.00+146.9%+139.6%$292.94M$20.76M0.00150Analyst ForecastZIOPZIOPHARM OncologyN/AN/AN/AN/A$187.12MN/A-2.01105Analyst ForecastXNCRXencor3.5491 of 5 stars$23.72+0.4%$35.75+50.7%+19.3%$1.65B$168.34M0.00280IMCRImmunocore2.9958 of 5 stars$32.42-0.4%$69.18+113.4%-28.7%$1.63B$249.43M0.00497Positive NewsNRIXNurix Therapeutics2.7301 of 5 stars$22.64-0.7%$29.40+29.9%+247.8%$1.61B$76.99M0.00300KNSAKiniksa Pharmaceuticals1.9939 of 5 stars$21.21+1.9%$36.60+72.6%+33.9%$1.50B$270.26M0.00220ARVNArvinas3.0807 of 5 stars$22.69+4.9%$61.08+169.2%+4.2%$1.49B$78.50M0.00445Analyst ForecastShort Interest ↓NTLAIntellia Therapeutics4.5389 of 5 stars$13.12-7.1%$54.94+318.7%-56.7%$1.44B$36.28M-2.41600Analyst ForecastAnalyst RevisionOCULOcular Therapeutix3.7464 of 5 stars$8.78-1.6%$16.71+90.4%+273.6%$1.40B$58.44M0.00267SYRESpyre Therapeutics2.3417 of 5 stars$27.50+2.2%$48.57+76.6%N/A$1.38B$890,000.000.00100High Trading Volume Related Companies and Tools Related Companies C4 Therapeutics Competitors ZIOPHARM Oncology Competitors Xencor Competitors Immunocore Competitors Nurix Therapeutics Competitors Kiniksa Pharmaceuticals Competitors Arvinas Competitors Intellia Therapeutics Competitors Ocular Therapeutix Competitors Spyre Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FHTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Foghorn Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
